<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04611893</url>
  </required_header>
  <id_info>
    <org_study_id>Crec 2020.376</org_study_id>
    <nct_id>NCT04611893</nct_id>
  </id_info>
  <brief_title>Monitoring of NOAC Therapy: Standardizing Reference Intervals</brief_title>
  <official_title>Monitoring of NOAC Therapy: Standardizing Reference Intervals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed to establish reference intervals of NOAC (dabigatran, apixaban and&#xD;
      rivaroxaban) in ethnic Chinese patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      360 patients who are on dabigatran, apixaban and rivaroxaban based on the above inclusion and&#xD;
      exclusion criteria will be recruited. After the informed consent, the patient will be needed&#xD;
      for blood taking before and 2 hours after the medication (NOAC). The patient's demographic&#xD;
      data and medical history will also be retreived from Central Medical Syetem too.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>NOAC level in blood</measure>
    <time_frame>One week after the recruitment</time_frame>
    <description>The NOAC level in blood before and after the medication</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Stroke, Acute</condition>
  <condition>Stroke Syndrome</condition>
  <condition>Ischemic</condition>
  <arm_group>
    <arm_group_label>Ischemic stroke patient</arm_group_label>
    <description>Ischemic stroke patients who are on dabigatran, apixaban and rivaroxaban based on the above inclusion and exclusion criteria will be recruited from the Prince of Wales Hospital, either in-patient or out-patient clinic</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood tests for haemoglobin level, platelet count, activated partial thromboplastin time&#xD;
      (aPTT), prothrombin time (PT), international normalized ratio (INR), creatinine clearance (by&#xD;
      Cockcroft-Gault formula), alanine aminotransferase, alkaline phosphatase, bilirubin, modified&#xD;
      thrombin time (dabigatran users), factor-Xa assay (for apixaban, rivaroxaban users) will be&#xD;
      performed at the same time as blood taking for NOAC levels.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are on dabigatran, apixaban and rivaroxaban based on the above inclusion and&#xD;
        exclusion criteria will be recruited from the Prince of Wales Hospital, either in-patient&#xD;
        or out-patient clinic.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ethnic Chinese ONLY&#xD;
&#xD;
          2. 18 years old or above&#xD;
&#xD;
          3. Non-valvular atrial fibrillation&#xD;
&#xD;
          4. Duration of NOAC use at least 3 months&#xD;
&#xD;
          5. No changes in NOAC dosage or type within 3 months&#xD;
&#xD;
          6. Creatinine Clearance (by Cockcroft-Gault formula) &gt;/=30mL/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Valvular atrial fibrillation or no atrial fibrillation&#xD;
&#xD;
          2. Recent haemorrhage or ischemia within 1 year&#xD;
&#xD;
          3. Active liver disease&#xD;
&#xD;
          4. Abnormal baseline clotting profile&#xD;
&#xD;
          5. Abnormal baseline thrombocytopenia or thrombocytosis&#xD;
&#xD;
          6. Thromboembolic tendency other than atrial fibrillation (e.g. antiphospholipid&#xD;
             syndrome, protein C, S, anti-thrombin III deficiency)&#xD;
&#xD;
          7. Non-compliant patients, defined as missing any doses of NOAC in recent 1 month&#xD;
&#xD;
          8. Anticoagulation for disorders other than AF&#xD;
&#xD;
          9. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yiu Ming Bonaventure IP, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yiu Ming Bonaventure IP, MRCP</last_name>
    <phone>852-35053856</phone>
    <email>iym984@ha.org.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yiu Ming Bonaventure IP, MRCP</last_name>
      <phone>852-35053856</phone>
      <email>iym984@ha.org.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. IP Yiu Ming Bonaventure</investigator_full_name>
    <investigator_title>Specialist Resident</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>ischemic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

